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Abstract (249 wds) 
Objective 
The reduction in body mass index standard deviation score (BMI-SDS) associated with 
improvement in biomarkers relating to metabolic health in obese children is unknown. We aimed 
to establish the change in BMI-SDS associated with improved inflammation, liver function and 
insulin resistance to inform clinical guidelines for paediatric weight management interventions and 
to assess the efficacy of future trials.  
Methods 
A large-scale systematic review was conducted to identify relevant studies. Studies of children 
with a diagnosis of obesity according to defined BMI thresholds, participating in lifestyle 
interventions to reduce obesity, were included. Studies must have reported baseline (pre-) and 
post-intervention (or change of) BMI-SDS and either fasting glucose, homeostatic model of insulin 
resistance (HOMA-IR), alanine aminotransferase (ALT), C-reactive protein (CRP), or interleukin-
6 (IL-6). A series of meta-regressions were conducted to establish links between BMI-SDS change 
scores and change in metabolic markers of health.  
Results 
Sixty-eight papers were identified. From the meta-regression analyses, across all study subsets, 
greater mean falls in all four parameters, (HOMA-IR, Glucose, ALT and CRP) were observed with 
greater mean loss of BMI-SDS, but the trends were only statistically significant for HOMA-IR 
and CRP (P=0.003; P=0.021). However, we could not find minimum changes in BMI-SDS that 
would ensure a fall in these outcomes. 
Conclusion 
At this time, we are unable to recommend a definitive value of BMI-SDS reduction needed to 
improve the markers of metabolic health. Future trials should aim to report additional indices of 
derived BMI values which may better reflect changes in actual adiposity. 
 





T2DM: Type 2 Diabetes Mellitus  
BMI-SDS: body mass index- standard deviation score 
RCT: randomised controlled trial 
IOTF: International Obesity Task Force 
HOMA: Homeostatic model assessment 
IL6: Interleukin 6 
ALT: Alanine Aminotransferase 
CRP: C-reactive Protein 
HTA: Health Technology Assessment  
SD: standard deviation 
SE: standard error 
CI: Confidence interval 
PI: Prediction interval 
















There has been a ten-fold increase in the number of obese children worldwide since 19751. 
Childhood obesity is associated with a range of health problems both in childhood and later life2. 
Conditions once limited to  adult populations, such as type 2 diabetes (T2DM) and fatty liver 
disease, are now being documented in children3. Not only is avoidable, sub-optimal health a concern 
for the obese individual, but the financial burden and stress that increasing obesity levels place on 
health services must not be overlooked4. Effective weight management programmes to tackle 
childhood obesity are therefore of importance.  
 
Weight-loss targets that can produce clinically useful reductions in risk have been established for 
obese adults5. Setting defined targets in children is more difficult as a result of the influence of 
growth. A standardised body mass index score (BMI-SDS) is used to assess weight status in children 
as they grow6, providing a normalised measure for the degree of obesity. The reduction in BMI-
SDS needed to effect clinically significant reductions in risk of metabolic factors is currently 
unknown.  
 
Insulin resistance  
 
Being overweight or obese may cause insulin resistance7. Evidence has shown that insulin resistance 
and glucose tolerance may improve through exercise and/or dietary modification8. Ford et al9 
demonstrated that a reduction of BMI-SDS ≥ 0.25 improved insulin resistance, with further benefit 
accrued if BMI-SDS was reduced by ≥ 0.5. Reinehr et al10 also investigated change in insulin 
sensitivity with regards to change in BMI-SDS. There was no change in insulin sensitivity for groups 
with small (BMI-SDS reduction of <0.25) or moderate (BMI-SDS reduction of ≥0.25 or <0.5) 
weight-loss. In the group that achieved large amounts of weight-loss (BMI-SDS reduction of ≥0.5), 






Insulin resistance and poor blood glucose regulation are interlinked with low-grade chronic 
inflammation as a result of increased adipose tissue11. Interleukin-6 (IL-6) and C-reactive protein 
(CRP) are two commonly reported inflammatory markers that are modified by increasing adiposity. 
IL-6 and CRP have both been linked  with increased insulin resistance and also contribute to 
atherosclerotic plaque development in adults12.IL-6 has been linked to detrimental health outcomes 
in obese children, such as endothelial dysfunction 13. A systematic review by Sirico et al14 in 2018 
reviewed the effect of physical exercise interventions (n = 7) on inflammatory markers in childhood 
obesity, and found reductions in both IL-6 and CRP. There is insufficient long-term data linking 
CRP levels in childhood directly to disease outcomes in adulthood, but early identification of such 




 Non-alcoholic fatty liver disease (NAFLD) is a complication of increasing adiposity, where fatty 
deposits develop within the liver. NAFLD is characterised by increasing levels of intrahepatic 
triglyceride content, with or without inflammation and fibrosis16.  A review by Anderson et al 2015 
found that the prevalence of NAFLD in childhood obesity clinics was 34.2%, in comparison to 
7.6% in children in general population studies17.  Raised levels of the hepatic enzyme Alanine 
Aminotransferase (ALT)  indicate liver damage and can be used as a marker for fatty liver 
disease18.  
 
Chronic inflammation as a result of obesity may cause hepatic insulin resistance, contributing 
further to overall insulin resistance, disordered glucose metabolism and metabolic syndrome, but 
the relationship between NAFLD and insulin resistance may be bi-directional19. Utz-Melere et al201 
 
 
undertook a review on the impact of lifestyle changes on BMI, aminotransferases and steatosis in 
children and adolescents with NAFLD (n=19 studies). They found the majority of the studies 
reported beneficial changes in ALT levels, reporting a combined effect. Using a random effects 
model, the standardised mean difference (SMD) was -1.35 but the confidence interval was wide 
(95% CI -1.92 to -0.78) as a result of heterogeneity in the studies. Further, Utz-Melere et al found 
that lifestyle improvements had a significant impact on steatosis, reducing risk by 61%. These 






This paper is part of a series of reports from a large-scale systematic review completed in early 2018 
(PROSPERO CRD42016025317). The aim of the review was to establish the changes in BMI-SDS 
necessary to effect improvements in metabolic health in obese children and adolescents. In total, 90 
studies were included (searched up to May 2017). The first paper focussed on the link between BMI-
SDS and measures of adiposity (using body fat %) (Birch et al.21) and another paper focusses on the 




We aimed to establish the minimum change in BMI-SDS associated with improvements in relation 
to blood glucose regulation, inflammation, insulin sensitivity/resistance, and liver function in obese 








The methods used to conduct the systematic review have been reported in detail in a previous 
publication (Birch et al21). Studies were identified by searching five electronic databases from 
inception to May 2017. A summary of the systematic review’s inclusion criteria and data extraction 
process can be found in Appendix 1. Specifically, this paper focuses on the following data extracted 
from the included studies: fasting glucose, Homeostatic Model Assessment of insulin resistance 
(HOMA-IR), IL-6, CRP, and ALT. 
 
Quality assessment  
Two members of the review team assessed the quality of the included papers using the Quality 
Assessment tool used in the 2004 Health Technology Assessment (HTA) systematic review of the 
long term effects and economic consequences of treatments for obesity and implications for health 
improvement22 (see Birch et al21 and Supplement 1 for further details).   
 
Deviations from protocol 
In the protocol for this systematic review (PROSPERO CRD42016025317) it was stipulated that 
no case-control studies were to be included. We allowed the inclusion of one study described as 
case-control33, but on closer inspection, this was actually a cohort study.  
 
Analysis 
We used random-effects meta-regression as implemented in Stata23 to separately quantify the 
relationship between the mean changes in BMI-SDS/z-score (independent, predictor variable) and 
mean changes in: (i) HOMA-IR, (ii) fasting glucose, (iii)ALT, (iv) CRP and (v) IL-6 (target 
variable), where the latter, target variables were either reported directly, or were able to be calculated 
from reported data. In each case, we were not trying to assess the relative effects of the various 
 
 
interventions, but rather to examine the relationships between the two sets of outcomes; meta-
regression allows for residual heterogeneity in the target variable not explained by the predictor.  
Essentially our approach was the same as that adopted in our first paper. Subgroups reported within 
the same study, however subdivided (i.e. intervention vs control, boys vs girls or good responders 
vs poor responders), were regarded as independent observations and used in preference to 
aggregated results from the whole study if both were reported. Standard deviations (SDs) were 
calculated from Standard Errors (SEs) or 95% confidence intervals (CIs) for the mean. If medians 
and ranges/interquartile ranges (IQRs) were reported rather than means/SDs, the latter were 
estimated from the former24; in one study25 which reported geometric mean and range for some 
target variables, the geometric means were used as a proxy for the medians. Analysis required the 
means/SDs of the changes in the target variables; where studies reported only pre- (baseline) and 
post- (intervention or control) values, values for the changes were estimated. SDs for the latter 
required a knowledge of the correlation coefficient between baseline and post-intervention results; 
we estimated these from studies reporting both sets of results and used their median. In our first 
paper21 we carried out sensitivity analyses using different values of R, the results were little changed. 
 
The fitted regression lines are plotted together with their 95% prediction intervals (PIs); individual 
points represent individual study subgroup results (the mean change in the target variable and the 
mean change in BMI-SDS) with the size of the surrounding circles representing the precision of the 
mean change in the target variable (i.e. the reciprocal of the SE squared). For a given mean change 
in BMI-SDS, the upper and lower limits of the 95% PI indicate the range of mean changes in target 









Ninety-eight published articles from 90 different studies met the inclusion criteria for the entire 
systematic review. The flow diagram (Fig. 1) illustrates the number of papers excluded at each stage 
of the review. Further information regarding the search results can be found in Supplement S1. 
 
Figure 1: Flow diagram of the systematic review that identified the included studies  




In total, 68 studies reported metabolic measures and details of these are listed in Table 126-100, 
alongside the outcome(s) of interest from each study. Whilst various glucose measures were 
reported, we focused on fasting-glucose measurements for this paper (56 studies), as fasting glucose 
is used clinically to identify pre-diabetes and diabetes. Although several insulin measures were 
reported, we focussed on HOMA-IR (66 studies) as a simple and routinely measured estimate of 
insulin resistance. The inflammation measures reported here are CRP (21 studies) and IL-6 (6 
studies). Finally, the measure of liver function reported here is ALT (21 studies).  
 
 
Narrative description of studies included in this paper  
 
Of these 68 studies, 47 were conducted in Europe, 15 in the Americas and six elsewhere in the 
world. Most studies defined obesity as a BMI-SDS>2 or a BMI percentile of at least the 90th 
percentile. Most of the studies were of cohort design (n = 49) and 16 were randomised controlled 
trials (RCTs). There was one study that adopted a quasi-randomised design30, one that was case-




Most interventions were conducted in hospital clinic settings (n=56). Six studies were interventions 
in the community and four in academic institutions. One group conducted their intervention between 
community and hospital clinic setting91,92, and one conducted their intervention between the 
community and academic institution37.    
 
Fifty-six studies conducted interventions that comprised both diet and exercise components. The 
remaining studies (n=12) utilised interventions that focused either on exercise or diet only.  
Duration of the interventions ranged from 2 to 24 months, with one study having no specific 
intervention period42. The majority of studies (n=59) did not report any follow-up after the lifestyle 
treatment intervention. The duration of follow-up in the studies where it was conducted and 
reported, ranged from 6 to 24 months.  
 
The sample sizes of the included studies ranged from 8 to 1017 participants. The age of the 
participants ranged from 4 to 19 years. Studies predominantly had a mix of males and females with 
only three studies specifically focused on either only girls61,62 or boys83. Forty studies (59%) 
measured the pubertal development stage of participants according to the Marshall and Tanner 
staging101, with pubertal status categorised into three groups: prepubertal, pubertal, and late/post-
pubertal. One study reported that pubertal development was measured but the method used was not 
defined37, and one study reported the percentage of prepubertal participants without defining how 
they measured puberty95. Twenty-six studies (38%) did not report any measures of pubertal 
development.  
 
Table 1: Characteristics of studies reporting adiposity outcomes 
(INSERT TABLE 1 HERE) 
 
 




Fifty-eight distinct studies had available data on HOMA-IR, with one omitted from analysis85 (as 
CIs derived from logarithmically transformed data made it impossible to ascertain SDs for 
HOMA-IR). The 57 studies yielded 105 useable data subsets after exclusion of one subset with 
incomplete data51. Means/SDs of the changes in HOMA-IR, however, were only available in 22 
of the 105. Fourteen of these also had pre- and post- mean/SDs and the median of the correlation 
coefficients (r) estimated for these was 0.66 (IQR: 0.25-0.75). This value was used to estimate 
the SD of the changes for each of the remaining 83 subsets.  
 
Figure 2 shows the results of the meta-regression of the relationship between mean change in 
HOMA-IR and the mean change in BMI-SDS across the 105 data sub-sets. The fitted regression 
line here is: Mean fall in HOMA-IR = 0.683 x Mean change in BMI-SDS -0.171. The slope 
was statistically significant (0.683, 95%CI 0.243-1.122, P=0.003), confirming a relationship 
between the variables across the study subsets, however from the prediction intervals it was not 
possible to determine a mean reduction of BMI-SDS that would ‘ensure’ a fall in mean HOMA-
IR in a future study since the upper limit of the 95% prediction interval was never wholly below 
0.  
Figure 2: Meta-regression of relationship between mean change in HOMA-IR and the mean 
change in BMI-SDS (n=105 subsets). 
 






The standardized predicted random effects were approximately normal (see Appendix 1 Figure 
A(i)).  A further analysis excluding two possible outliers (with mean change in HOMA-IR>2) 
 
 
produced very similar results (results not shown). In separate analyses, the %females were added 
to the regression model. The %females was not statistically significant (P=0.30).  
 
Appendix 2 also contains further analyses. Figure A(ii) highlights (in red) the four study subsets 
where geometric means were used interchangeable with medians (see Analysis section above). 
These four results seemed consistent with the remainder and their exclusion did not change our 
overall findings. Figure A(iii) shows the analysis of the 22 subsets where the mean/SD of the 
changes in HOMA-IR were obtained directly from the research documentation (thus avoiding 
using an estimate of r). 
 
Fasting Glucose  
There were 52 distinct fasting glucose studies, with one omitted from analysis58 as it was not 
possible to ascertain glucose SDs. The remaining 51 studies yielded data on 93 subsets; but one 
was unusable65 (one subset too small to estimate glucose SD from IQR). Only eight of the 
remaining 92 study subsets provided mean/SD of the changes in glucose values. Across these 
there was no significant relationship with mean change in BMI-SDS (data not shown), but the 
number of studies was small and spanned only a narrow range of BMI-SDS changes.  The 
median of the correlation coefficients estimated from three subsets that provided SDs for the pre-
, post- and change in glucose measurements was 0.69 (range 0.53-0.92). Using this, the SDs of 
the changes in glucose were estimated for the remaining 84 subsets.  
The resulting meta-regression on the full data set (n=92) is shown in Figure 3 below. The meta-
regression line fitted was: Mean fall in Glucose = 0.069 x Mean change in BMI-SDS -0.008. 
There was a small positive slope which was not statistically significant (0.069, 95%CI -0.025 to 
0.163, P=0.15). From the prediction intervals, it was not possible to determine a mean reduction 





Figure 3: Meta-regression of relationship between mean change in fasting glucose and the 
mean change in BMI-SDS (n=92 subsets) 
 
INSERT FIGURE 3 HERE 
 
A half normal plot for the standardized predicted random effects, shown in Figure B(i) of 
Appendix 2, suggested two possible outliers, each from different studies but both with mean 
change in fasting glucose<-0.5 in Figure 3 above. Exclusion of these two outliers did not change 
the overall findings (Appendix 2 Figure B(ii)). 
When added to the meta-regression, the %females in the subset did not significantly affect the 




Twenty studies provided data on ALT, with two omitted from analysis85,89 (one used geometric 
means for BMI-SDS and there was uncertainty with the other whether range or IQR for ALT 
was reported). The remaining 18 studies yielded 28 subsets for analysis. Only four subsets 
provided mean/SD of the changes in ALT, too few for separate analysis. Two of these provided 
SDs for each of the pre-, post and changes in ALT; correlation coefficients estimated from the 
latter were 0.97 and 0.88; their mean/median value of 0.93 was used to estimate the SD of the 
changes in ALT for the remaining 24 subsets. 
The meta-regression on the full data set (n=28) is shown in Figure 4. 
The meta-regression line fitted was: Mean fall in ALT = 4.00 x Mean change in BMI-SDS – 
3.90. The slope was positive but not statistically significant (4.00 95%CI -3.03 to 11.02; 
P=0.253). From the prediction interval it was not possible to determine a mean reduction in 
 
 
BMI-SDS to ensure a mean fall in ALT. A half normal plot for the standardized predicted 
random effects, is shown in Figure C(i), Appendix 2. 
 
Figure 4: Meta-regression of relationship between mean change in ALT and the mean 
change in BMI-SDS (n=28 subsets) 
 
INSERT FIGURE 4 HERE 
 
 
What added to the meta-regression the %females were significant determinants of the change in 
ALT (p=0.80).  
A further analysis which excluded a potential outlier subset (with change in ALT<20 in Figure 5 
above) did not change the results.  
 
CRP  
Nineteen studies provided data on CRP with one omitted from analysis60 (as it presented logged 
values) yielded 36 data subsets for analysis. Only three subsets yielded mean/SDs for the change 
in CRP but all 3 had pre- and post- SDS as well and therefore could be used to estimate 
correlation coefficients. The median of these was 0.69 (range 0.58-0.80) which was used to 
estimate the SD of the changes in the remaining 33 studies. The meta-regression for the full data 
set (n=36) is shown in Figure 5.  
The regression line was Mean fall in CRP = 0.48 x Mean change in BMI-SDS + 0.03,  
The positive slope was statistically significant (0.48, 95%CI 0.08-0.89; P=0.021) although from 
the PIs it was not possible to determine a change in mean BMI-SDS that would ensure a fall in 
CRP.  A half normal plot for the standardized predicted random effects, is shown in Figure D(i) 




Figure 5: Meta-regression of relationship between mean change in CRP and the mean change 
in BMI-SDS (n=36 subsets) 
 
INSERT FIGURE 5 HERE 
 
As was the case with HOMA-IR, the CRP data in Ford et al 2010(b) had been expressed as 
geometric means and used here as proxys for medians; analysis excluding these four subsets 
however did not change the findings. When added to the meta-regression model, neither %females 
related to the change in CRP (P=0.48). 
 
IL-6 
As only six studies reported IL-6, we deemed it appropriate to report just a narrative description of 
the data (represented as mean (SD)). The mean baseline BMI-SDS was 3.51(1.04), the mean end of 
intervention BMI-SDS was 2.97 (0.76) and the mean change from baseline to the end of intervention 
was -0.54 (0.49). The mean baseline levels of IL-6 were 2.04 pg/ml (0.58), and the mean end of 















Summary of main results 
The objective of this paper was to attempt to establish the minimum change in BMI-SDS needed 
to achieve improvements in metabolic health in this population. Sixty-eight papers reported on the 
parameters of interest in this paper (HOMA-IR, fasting glucose, ALT, CRP).  
From the meta-regression analyses, across all study subsets, greater mean falls in all four 
parameters (HOMA-IR, fasting glucose, ALT and CRP) were observed with greater reduction of 
BMI-SDS, although the trends were only statistically significant for HOMA-IR and CRP 
(P=0.003; P=0.021). Looking specifically at the prediction intervals, however, we could not find 
minimum changes in mean BMI-SDS that would ensure a fall in these outcomes. Our model hinted 
that a greater change in mean glucose might be obtainable for the same change in mean BMI-SDS 
achieved over a longer duration, but further evaluation was difficult. 
 
Strengths and limitations  
We believe that this is the first paper to attempt to bring together all studies that have reported both 
a change in BMI-SDS and changes in markers of metabolic health, including liver function, in the 
obese paediatric population. In some cases, there were variations in reporting of results where 
multiple publications reported on the same study; where this occurred the results from the most 
comprehensive paper were used (See Supplementary material S1). Consideration to the strengths 




Agreements and disagreements with other research 
Whilst there has been previous evaluation of the effects of lifestyle interventions for treating 
overweight and obesity in children and adolescents 103,104,105, the main focus of these reviews has 
 
 
been the change in BMI and BMI z-score achieved, and few have examined the effects on 
metabolic risk. Our findings regarding improved CRP with BMI-SDS reduction are in line with 
the findings from a systematic review by Sirico et al14, who reviewed the effect of physical 
exercise interventions on inflammatory markers in childhood obesity reporting CRP reductions 
alongside IL-6. Our analyses also identified a statistically significant reduction in insulin 
resistance (measured as HOMA-IR) associated with BMI-SDS reduction. A systematic review 
and meta-analysis conducted by Ho et al106 of the effects of lifestyle interventions on cardio-
metabolic outcomes in overweight and obese children, identified 15 studies which reported 
fasting insulin. The results of their meta-analysis indicated that lifestyle interventions produced 
significant weight-loss compared with no-treatment control conditions (BMI: -1.25kg/m2, 95% 
CI -2.18 to 0.32; BMI z-score: -0.10, 95% CI -0.18 to -0.02) and led to significant improvements 
in fasting insulin (-55.1pmol/L, 95% CI -71.2 to -39.1). 
 
Clinical implications 
The findings from our meta-regressions indicate that a reduction in BMI-SDS is associated with 
improvements in insulin resistance (HOMA-IR) and inflammation (CRP). However, from these 
analyses, we are currently unable to set any specific parameters for the required change in BMI-
SDS needed to affect positive clinical outcomes. More evidence is needed before such parameters 
can be identified and used in a clinical setting. 
 
Recommendations for future research 
Given the apparent lack of evidence that changes in BMI-SDS accurately reflect changes in 
metabolic health with childhood obesity, it seems prudent for future trials to report additional 
indices of derived BMI values which may better reflect changes in actual adiposity. In addition, if 
the studies included were of longer duration, a greater improvement in some of these markers 






At this time, based on the findings of this review, we are unable to recommend a definitive value 
of BMI-SDS reduction needed to improve the markers of metabolic health (Fasting glucose, ALT, 
IL-6). Despite significant trends in reduction of BMI-SDS in relation to both HOMA-IR and CRP, 
we were unable to identify minimum changes in BMI-SDS that would ensure a fall in these 
outcomes. Future trials should aim to report additional indices of derived BMI values which may 
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Table 1: Characteristics of studies with outcomes reported 
 
 












Mean ± (SD) 














1 Aeberli, 201026 & 
Murer 201127, 
Switzerland  
Cohort: Total: 203 BMI > 98th %ile Aeberli: Age range:10-
18: 
14.1 ± 1.9 
 F=42% 
Murer: Age range: NR  
14.1 ± 2.0 
F=44% 
NR  D+E: 
Clinic/ 
hospital 
Moderate caloric restriction.2 x 60-90min/day 
endurance exercise + 4-5 hr/wk. exercise session 






2 Bell 200728, 
Australia 
Cohort: Total = 14 BMI >95th %ile Age range: 9-16: 12.7  
± 2.32  F= 43% 
Yes- Tanner E 
(Community) 
8 weeks structured circuits exercise training: 3 x 







3 Bock 201429 
Canada 
HIP KIDS  
Cohort:     
Total = 42                            
BMI ≥ 95th %ile 
(CDC) 
Age range: 8-17 
12.8 ± 3.14 
F=50% 
Yes - Tanner D+E: 
Clinic 
(Hospital) 
Intensive phase (3 mths): bi-wkly 90 min 
counselling. Maintenance phase (9 months): 
alternating mthly gp or individual sessions (90 
mins). Sessions focus on 





glucose,  and 
ALT 
4 Bruyndonckz 
201530, Belgium  
Quasi-randomised 
trial: 
Total = 61  
I = 33  
C = 28                                       
BMI ≥ 97th %ile 
adolescents <16 
yrs;                                              
BMI ≥ 35 
adolescents ≥ 
16 yrs 
Age range: 12-18 
iI: 15.4 ± 1.5                                                                
C: 15.1 ± 1.2 
F=75% 
NR  D+E: 
Clinic
(Hospital) 
Intervention: Dietary restriction 1500-1800 
kcal/day + 2 hrs/day supervised play/lifestyle 
activities + 2hrs/wk PE + 3 x 40min/wk 
supervised training session.  









Cohort: Total = 50 
(28 completed)                                      
CDC Age range: NR  
9.5 ± 1.9 
F=47.6% 
NR  D+E: 
Academic 
Institution 
Nutrition/behavioural modification session 40 
min/wk + PA 50 min x2/wk+ Family support 







6 Calcaterra 201332                                       
Italy  
Cohort:
Total = 22                          
BMI > 95th %ile Age range: 9-16 
13.23 ± 1.76 
F=41% 
Yes - Tanner E: academic 
institution 




















Balanced normocalorie diet (30% fat + 15% 
protein + 55% CHO) + Limited 2hr/day tv/video 











Total = 103 
(Obeldicks - Mini) 
>97th to 99.5th 
%ile  
Age range: 4-8 yrs 
















Total = 44  
I = 22,  
Obese C =22 
BMI > 97th %ile  Age range: 6-11. 
8.9 ± 1.5 
F=64% 
Yes- Tanner  E 
Clinic 
(Hospital) 






10 Ford, 2010 
A+B9,36  UK  
RCT: 
Total = 106           
BMI ≥ 95th %ile 
(CDC)  
Mandometer: 9.0 - 
16.9 
SC: 9.1 - 17.5                                               
Mandometer: 12.7 ± 
2.2 
SC: 12.5 ± 2.3                                           
F=56% 
Yes- Tanner D 
Clinic 
(Hospital) 
Mandometer device to regulate rate of eating and 




and CRP.   
11 Gajewska, 201637 
Poland. 
Cohort: 
Total = 100 
BMI SDS > 2 Age range: 5-10. 
8.1 (6.8-9.2) with 














3-mth intervention, low energy diet (1200-
1400kcal), 3-5 meals every day, instructions 







38, 2011 Poland.  
Cohort: 
Total = 50 
BMI > 97th %ile 
(ref data for 
Polish children) 
Age range: 8-18 
14.2 ± 2.6 
F=58% 
Yes- Tanner D+E: 
Clinic 
(Hospital) 
Exercise therapy (Instructions in PA + reducing 







and IL-6.  
13 Gronbaek 201239 
& Kazankov 2014 




 Total = 117 (71 




Age range: NR  
12.1 ± 1.3 
F=56% 
NR  D+E: 
Community 
Individually designed healthy diet + moderately 







and ALT.  
14 Grulich-Henn 
201141,  Germany  






Age range: 8-17. 
(median) 12.6. 
F=58% 
NR D+E: Clinic 
(Hospital) 
6 x monthly nutritional consultation & cognitive 








201442                                                           
Iceland  
Cohort: Total=110 BMI z-score > 
2.0 SDS 
(Swedish 
growth curve)  





Family-based Epstein behavioural intervention. 3: 
0 
ALT 




BMI > 95th %ile 
(CDC) 
 
Age range: 10-16.  
11.9 ± 1.4 
F=42.6% 
 
Yes- Tanner D+E  
Clinic 
(Hospital)  
Parents (4 sessions/wk lifestyle support in 1st 
month + 15 min/month telephone session) + 
Children (Low calorie diet + 30 min/day brisk 
walk for 1st 2 wks, then 1 hr by 3rd wk + 











BMI > 95th %ile 
(CDC) 
 
Age range: 10-16.  
13.6 ± 1.3. 
F=41% 
 
Yes- Tanner D+E.  
Clinic 
(Hospital) 
Parents (4 sessions/wk lifestyle support in 1st 
month + 15 min/month telephone session) + 
Children (Low calorie diet + 30 min/day brisk 
walk for 1st 2 wks, then 1 hr by 3rd wk + 









201245 Finland  
RCT: Total=70  Wt-for-ht 115-
182% 
 
Age range: 6.6-9.7. 
8.1±0.8    
F=60% 
Yes- Tanner D+E. 
Community 
2 interventions (Group and routine) - Routine (2 
school heath care sessions) + Group (10 x 90 








healthy lifestyle/physical activity session, then 
next 5 sessions/2 wks + 1 session together)  6 






35 kgm² OR 
BMI-for-age > 






Age range: 8-18.  
Inpt tx: 14.9 ± 2.5                                                     
Ambulatory tx: 14.4 ± 
2.1                                                        
Usual care: 14.7 ± 2.4. 
Inpt tx F=56%                                     
Ambulatory tx F=24%                                                       
Usual care F=50% 
 
Yes -Tanner D+E.  
Clinic
(Hospital). 
Long inpt (6 months tx on working days + 
follow-up of 6 monthly return visits of 2 days); 
Short inpt (2 months tx on working days + 4 
months biweekly return visits of 2 days + follow-
up 6 monthly return visits of 2 days); 
Ambulatory setting (16 days ambulatory visits at 
increasing time-intervals over 6 month period + 
follow-up ambulatory visits 6 wks, and 3, 6, 9, 
12 months after end of treatment); Home-based 
usual care (6 month continuation of care in local 
setting). Interventions focused on 
nutrition/behavioural sessions, increasing 






of 6 monthly 
return visits 
of 2 day 
HOMA-IR 












NR D: Clinic  Low glycemic index, glycaemic load and 
fructose diet. 1 session of education for parents 
and children, then monthly follow up calls to 









21 Makkes 201648, 
The Netherlands.  
 






99.9th 4th Dutch 
national growth 
study of 1997. 
SDS-BMI equal 
to or over 3.0 or 
SDS-bmi equal 
to or over 2.3 + 
obesity related 
comorbidity 
Age range: 8-19 Total: 
14.8 +/- 2.3 SS (2 
mths): 14.5 +/- 2.4. LS 
(6 mths): 15+/- 2.2 
Total F=66% SS F= 
70% LS  
F =63% 
NR D+E: Clinic 
(Hospital) 
Treatment: Focused on nutrition, physical 
activity and behaviour change and required 
active participation of parent/caregiver. 
1 year, with 1 
year follow 









 Ob: BMI>97th 
%ile/BMI z-
score >2 




Yes- Tanner D+E: Clinic 
(Hospital) 
Nutrition + PA recommendations + A form to 
register weekly hours of physical activity, 
number of steps taken/day, and hrs/wk spent in 
sedentary activities + Restrict calorie intake and 








glucose,  and 
CRP.  
23 Martos 200950 
Spain  
Cohort:  
Total = 47 




Age range: 6-9. 
8.0±0.15. F=60% 
Yes- Tanner.  D+E: 
Community 
Moderately ob subjects (Low-calorie diet); 
Severe/refractory ob subjects (Restriction diet of 
25-30%) + Moderate/intense exercise 60 min/day 






and IL-6.  
24 Meyer 200651 
Germany  
RCT: 
Total = 67  
(I = =33 
Obese C=34)                                 




Age range: 11-16 
I: 13.7 ± 2.1                          
Ob C: 14.1 ± 2.4 
F=48%  
Yes - Tanner E: 
Clinic 
(Hospital) 
3 x exercise sessions (Monday: swimming and 
aqua aerobic training 60 min + Wednesday sports 
games 90 min + Friday walking 60 min)/ wk;  





25 Miraglia 201552 
Brazil  
Cohort: 
 Total = 27                                 







AmO: Outpatient Ambulatory. Obesity 
outpatient clinic - lifestyle change based on goals 
agreed relative to feeding habits & physical 






assessed at inclusion & after 12 mths of FU to 
obtain anthropometric & adipokine 
measurements. 
26 Montero 201453, 
Spain  





Age range: NR.  
13.45 ± 1.18. F=70%.  
 




Moderately hypocaloric diet (reduction of 
between 300-500kcals) while performing 
physical activity programme of 4x90 minutes 










 Total = 40            
 
 
OW/Ob as per 
Cole et al 2000 
criteria 










Moderate energy-restricted diet + nutritional 












 Total = 53                                                
NR  Age range: 5-13. 
Responders: 9.0 ± 1.1  




Yes -Tanner D+E: 
Community 
Educational Wt Excess Reduction Program  24:  
>6 months 
HOMA-IR 
29 Obert 201357, 
France  
Cohort: Total = 28 BMI>97th %ile Age range:  NR. 
14.2±1.5. 
F=47%.  
NR D+E: Clinic 
(Hospital) 
Cycle ergometer (9 x 5 mins x 3 times/week: 4 
min moderate + 1 min intense) + 2 times/wk 
moderate exercise for 1st 2 months, then 5 
times/wk next 7 months + PE lessons + Total 
calorie intake 2300-2500 kcal/day. 
 
9:0  HOMA-IR, 
and fasting 
glucose. 
30 Pacifico 201358  
Italy  
Cohort: 
 Total = 120                                    








Hypocaloric diet (25-30 cal/kg/day) + 60 
min/day ~ 5 days/wk moderate exercise + 









201159  Canada  
Cohort: Total=119  
 
Ob: BMI ≥ 95th 
%ile OW: BMI 
≥ 85th %ile and 
<95th %ile with 
at least 1 
comorbidity 
Age range: 6-17. 11.6 
± 2.6. F=43% 
NR D+E: Clinic 
(Hospital) 
10 x consecutive weekly group sessions (6-10 











BMI z-score >2 Age range: HGI diet: 
8.1- 12.5                               
LGI diet: 7.7- 13.0.  
HGI diet: 9.8 ± 1.6                                     





6 months: Participants randomised to a 








33 Racil 201361 
Tunisia  
RCT : 
 Total = 34 
HIT=11  
MIIT =11 
OC=12                                         
BMI > 97th %ile 
(French 
standards)  
Age range: NR  
HIIT: 15.6 ± 0.7                            
MIIT: 16.3 ± 0.52 
F=100% 
Yes -Tanner  D+E: 
Community 
4-day diet records + HIIT or MIIT. Interval 







34 Racil 201662 
Tunisia  
RCT: 
Total = 47 HIIT 
=17 MIIT16  
OC =14                                                       
BMI > 97th %ile 
(French 
standards)  
Age range: NR 




HIIT (Warm up + Interval training at 100%/50% 
MAS + Cooling down);  
MIIT (Warm up + Interval training 80%/50% 












BMI z-score>2 Age range: 11-15. 




Nutritional/health risks sessions, 5 hrs/week 













Total = 42                              
BMI ≥ 97th %ile  Age range: 6.1-15.1 
10.2 
F=57% 
Yes - Tanner  D+E: 
Clinic 
(Hospital) 
Obeldicks - Intensive phase 3 mnths (Parents' 
course 2x/month + Behaviour therapy 2x/month 
+ Nutritional course 2x/month + Exercise therapy 
1x/wk) + Establishing phase 3 mnths (Talk 
rounds for parents 1x/month + Psychological 
therapy + Exercise therapy 1x/wk) + Establishing 
phase 2 for 3 mnths (Psychological therapy + 
Exercise therapy 1x/wk) + Establishing phase 3 






37 Reinehr, 2004b65 
Germany  
Cohort: Total=57  BMI ≥ 97th %ile  
 
Age range: 6-14 
(median: 10 years). 
F=54% 








38 Reinehr 2004c66 
Germany  
Cohort: Total=130 BMI ≥ 97th %ile  
 
Age range: 4-15. 10.7.  
F=53%.  












BMI ≥ 97th %ile  
 
Age range: 6-14. 10.4. 
F=46.7% 









40 Reinehr 2008a68, 











Age: Obese: 10.8 ± 
2.6; 
F=61% 
 Lean C: 10.3±2.9  
F=58% 
(p<0.873) 














Age range: 6-16. NR.  
Intervention F=47%. 
No intervention F= 
40% 





42 Reinehr 2009b71 
Germany  




Age range: 10 to 16. 
mean 12.5. median 
13.3. IQR 11.3-13.5. 
F=55% 















Age range: 6-16. NR.  
F=50% 









44 Rijks 201573  
Netherlands  
Non-randomised 
prospective study    
Total = 145                    
IOTF criteria: 
Ow, Ob, MO 
Ages: Ob: 2.6 - 18.9                                    
Morb. ob: 4.1 - 18.9 
Ob: 11.4 ± 3.2                                           
Morb. ob: 12.3 ± 3.4 
Ob: F=57   %                               




Guidance with focus on nutrition, food habits, 






45 Rohrer 200874                                                   
Germany  
Fit Kids  
Cohort:
 Total = 22                          
BMI > 99.5th 
%ile (German 
standard values) 






NR  D+E: 
Community 
Physical exercise (2 x wk, 100 hrs in total) + 
Nutritional/heath education and psychological 
care for the child (x wk, 43.5 hrs total) and 








factors or BMI 




46 Roth 201175 Cohort: total=62 
 
>97th Centile  Age range: NR. no sig 
weight loss 11 ±0.4 
years. Weight loss 11 
±0.5 years. F=54%.  
% prepubertal  D+E. 
Community.  









Total = 69                                  
Ob as per IOTF 
criteria
NR - Obeldicks age 
range 
Ob with wt loss: 11.8 
± 2.0     
F=50% 
 Ob without wt loss: 
12.1 ± 2.1  
F=51%                    
Normal wt: 12.3 ± 3.0 
F=45% 
Yes - Tanner D+E: 
Clinic 
(Hospital) 











BMI ≥ 97th %ile Age range: 9-14. 12.1 
± 1.7. F=56%.  
Yes- Tanner.  D+E:  
Clinic 
(Hospital)  
12 x monthly visits in 2 phases: motivational and 
intervention. Focus on promoting healthy eating, 







49 Santomauro 2011 
78 Venezuela  




Age range: 7-18.  
10.59 ± 2.96.  
F=42% 
 
Yes-Tanner D+E: Clinic 
(Hospital) 
Dietary recommendations + 30 mins daily 
moderate exercise or 3 x week moderate exercise 







and ALT.  
50 Savoye 200779, 
201180 
USA 
Bright Bodies  
RCT 
+ 
Long term FU 
results (cohort)    
 
Total = 174 
 I (BB)=105 
Clinic C=69  
 
FU Total = 159 
(n=143 analysed)   
BMI ≥ 95th %ile 
(CDC)  
Age: 8-16 
BB: 12.0 ± 2.5   
F=55% 
                                   




13.9 ± 2.4 
F=62% 
NR D+E, 





 Bright Bodies (BB) Weight Management 
Program: nutrition education, exercise, 
behavioural modification. 
2 x sessions/wk for 6 mths, then biweekly for 
next 6 mths.  
BB: 2x50 min exercise + 1x40 min 
nutrition/behaviour modification per wk  
+ 12 mths no active intervention. 
  Control group: std care – paed. obesity clinic 
(biannual clinic appt; diet + exercise counselling)   
Structured tx & teaching program (28 x 45 min 
















Total = 75 
BB=38 
CC =37 
BMI ≥ 95th %ile Age range: 10-16 




Yes- Tanner D+E: 
Academic 
Institution 
BB weight management program- 2days/ week 






52 Schum 201282 
Germany  
Cohort: 
Total = 25 (n=10 
SMP, n=23 BFC) 
BMI ≥ 95th %ile Age range:11-16 





BB Weight Management Program - 2 days/week 
30 min exercise sessions + 1 day/week 45 min 









53 Seabra 201683                                      
Portugal   
Cohort: 




 OC =30                                                        
BMI-SDS > 2  8-12 
Soccer: 10.5 ± 1.5                                                     
Trad. activity: 11.0 ± 
1.6 
F=0% 
Yes - Tanner E: 
Community 
Soccer & trad. activity programmes (3 x 60-
90min/wk) + 2 x 1hr at BL & 3 mnths later 







54 Shalitin 200984 
Israel   
Cohort:  
Total = 174 
randomised 
 E =52  
D =55  
D+E = 55 
BMI > 95th %ile 





Yes - Tanner  D+E: 
Clinic 
(Hospital) 
D +E 3-month interventions: Exercise 
intervention (90 min moderate exercise 3 
days/wk);  
Diet intervention 3 mths (12 x/wk nutritional 
group meetings with parents + Hypocaloric diet 
1200 kcal/day); 
 Diet and exercise intervention 3 mths (90 min 
training session days/wk + 12 x/wk nutritional 
group meetings with parents + Hypocaloric diet 
1200 kcal/day). 





and IL-6.  




BMI > 90th %ile Boys: 13.2-14.5   




Yes -Tanner D+E: 
Clinic 
(Hospital) 
Encouraged to increase exercise by 1-2 hrs/day + 
Decrease sedentary behaviour to a total of 2 
hrs/day or less + Nutrition recommendations + 6 





56 Truby 201686 
Australia  
RCT: 
 Total = 87 SMC 
=37, SLF=36  
WL OC =14                                      
BMI > 90th %ile 
(CDC)  
10-17 
modified CHO diet: 
13.2 ± 1.9     
F=73%                                    
Low fat diet: 13.2 ± 
2.1       
F=72%                                                   
Control: 13.6 ±1.9  
F=71%  
Yes- Tanner D: 
Clinic 
(Hospital) 
Structured modified CHO diet (35% CHO; 30% 
protein; 35% fat), structured low-fat diet (55% 
CHO; 20% protein; 25% fat),  





and ALT.  
















(IQR)                                                           
Obese control: 10.3- 
14.1 (IQR). F=57%.  
Yes- Tanner D+E: Clinic 
(Hospital)  
Intensive phase 3 months (Parent course 
2x/month + Behaviour therapy 2x/mnth + 
Nutritional course 2x/mnth + Exercise therapy 
1x/wk) + Establishing phase 3 mnths (Talk for 
parents 1x/mnth + Psychological therapy + 
Exercise therapy 1x/wk) + Establishing phase 2 
next 3 mnths (Psychological therapy + Exercise 
therapy 1x/wk) + Accompanying families back to 




58 Valle Jiminez 
201388 Spain 
Cohort: Total=50 BMI >95th%ile 
growth curves 
for the Spanish 
population  
Age range:  
6.0-9.0. 8.02±0.15. 
f=58% 
Yes- Tanner D+E: Clinic 
(Hospital) 
Behavioural components, physical exercise and 
nutritional education. Energy distribution of diet: 
25% between breakfast & lunch; 30-35% at 
lunch; 15% afternoon snack; remainder dinner. 
Moderate-to-intense PA for 30 mins at least 3 
days per wk. Aim that 1 month after the start of 
tx subjects should be engaging in 60 mins/day 






59 Van Hoorenbeck 
201389 Belgium  
Cohort: Total=224 
(197 analysed) 
ND. BMI Z 




±0.42 ODI≥2 = 
2.78±0.41 
Age range: ODI < 2: 
10.2-18.0                                         
ODI ≥ 2: 10.1-18.0.  
ODI < 2: 15.4                                                                
ODI ≥ 2: 15.9 
ODI<2:F=74%. ODI 
≥2 F= 48%.  
NR D+E: Clinic 
(Hospital). 
Moderate dietary restriction (1400-1600 
kcal/day) + Min 10 hrs/wk physical exercise + 






and ALT.  




Total = 90  
Inpt. = 45 (37) 
AmO = 45 (36)                          
BMI z score ≥ 




Age range: 8-18 
Inpt: 13.8 ± 2.3; 
F=58%    
AmO: 13.9 ± 2.5; 





Inpt. (Hospitalised 26 wks on working days - 4 
days/wk 30-60min exercise + nutrition/BM 
once/wk + parents/caregivers 3 x 1hr lesson on 
nutrition/BM);  
Ambulatory (12 visits at increasing time intervals 
- 1 hr exercise session + encouraged 3 x 
exercise/wk + 1 hr educational programme + 30 






 and ALT 
 
61 Verduci 201191 & 
Pozzato 201092, 




curve cut-off 30 
kg/m2 or cut-off 
18.5-25 kg/m2 
at 18 yrs  
 Age range: 6 to 14. 
NR. 
F=58%. 
Yes-Tanner D+E: Clinic 
(Hospital) + 
Community 
Normocaloric balanced diet + 1 hr nutritional 








62 Verduci 201593 
Italy  
RCT: 
 Total = 90  
Inpt. = 45 
ambulatory = 45                                 
BMI z score ≥ 





Inpt: 13.8 ± 2.3     
F=58%      
Ambulatory: 13.9 ± 
2.5    
F=58%                 
NR  D+E: 
Clinic 
(Hospital) 
Inpt. (Hospitalised 26 wks on working days - 4 
days/wk 30-60min exercise + nutrition/BM 
once/wk + parents/caregivers 3 x 1hr lesson on 
nutrition/BM);  
Ambulatory (12 visits at increasing time intervals 
- 1 hr exercise session + encouraged 3 x 
exercise/wk + 1 hr educational programme + 30 





glucose.   
63 Visuthranukul 
201594, Thailand  
RCT: 
Total = 70 
randomised.  
I = 25  
OC=27 analysed                                     
ND. BL BMI z-
score:  
I = 3.7 ±0.9 
C = 3.6±1.6  
9-16 
I = 11.9 ± 1.9   
F=36%                                                                      
C = 12.0 ± 2.1  
F=30% 
Yes- Tanner D: 
Clinic 
(Hospital) 
I (Low GI diet + Energy restriction 1400-1500 
kcal/day + Increased exercise);  
OC (Energy restriction 1200-1300 kcal/day + 







64 Vitola 200995, 
USA  
Cohort: 
Total = 8 
 
 
BMI ≥ 95th %ile Age range: NR 
15.3± 0.6 
F=12.8% 
Yes- Tanner D+E: 
Clinic 
(Hospital) 
Behavioural goals for reducing calorie intake and 














Cole et al 
criteria 
Age range: 8-17 
I: 13.3 ± 2                                                                      
C: 13.1 ± 1.9 
F=55% 
Yes - Tanner D+E: 
Clinic
(Hospital) 
12 mnths: During first 3 mnths (7 x 2.5 hr/2 wks 
children group meetings + 5 x 2.5 hr/2 wks 
parent meetings + 1 x 2.5 hr/2 wks child/parent 
meeting + 2-3 refresher follow-up sessions for 









66 Weiss 200997                                               
USA  
Cohort: Total=186 BMI > 95th %ile 
(CDC) 
 
Age range: 6-18.  
13.1 ± 2.5. F=57%.  
 
NR D+E. Clinic 
(Hospital).  
Subjects followed biannually as outpatients + 
Received nutritional/PA guidance. Levels of 
adherence to these recommendations was not 








67 Wickham, 200998  
& Evans 2009 99 




Total = 168 (64) * 
  
BMI ≥ 95th %ile 
(CDC)  
Age range: 11-18 
13.4 ± 1.8; F=60% 




E 1 day/wk at facility + 2 additional E days at 
facility of ppts’ choice + 30 min/wk nutrition 






68 Wunsch 2006 100 
Germany  
Cohort: Total=56.  BMI > 97th %ile  
 
Age range: 8.3-9.1. 
8.7. F=66%.  
NR D+E:  
Clinic 
(Hospital) 






KEY: %ile = percentile; AmO = Outpatient Ambulatory; An. = analysed; apt. = Appointment; BB =Bright Bodies; BFC = Better food choices; BL = baseline; BM = behaviour modification; 
BMI= body mass index; C = control; CG: control group; CBT = cognitive behavioural therapy; CDC = Centre for Disease Control; CG = control group; CHO = carbohydrate; D = diet; E = 
exercise; FBBT = family-based behavioural treatment; F = female; FU = follow up; GI = glycaemic index; GT = group therapy; HGI = high glycaemic index; hr = hour; ht = height; I = 
intervention; IG= intervention group; IOTF = International Obesity Task Force; Inpt. = inpatient; LGI = low glycaemic index; LMS= least-mean-squares; LS = long stay; min= minute; mth = 
month; MO = morbidly obese; norm. normal; n = number; NAFLD = Non-alcoholic fatty liver disease; ND = not described; NR = not reported; OB = obese; OC = obese control; OW = 
overweight; paed. = paediatric; PA = physical activity; PE = physical activity; PROT= protein; RCT = randomised controlled trial; SD = standard deviation; SDS = standard deviation score; 
SMP= Structured meal plan; SS= short stay; SMC= structured modified carbohydrate diet; trad. = traditional; Trad. act = traditional activity; tx = treatment; wk = week; WList OC– wait list obese 
control; WL = weight loss; wt = weight; X-over = crossover; yr = year CRP=C-reactive protein; ALT=Alanine Aminotransferase; IL-6=Interleukin-6; HOMA-IR= Homeostatic model assessment 






























Figure 1 Flow diagram to show the search results and various stages of exclusion for the 
systematic review.  
 
Table 1: Characteristics of studies reporting adiposity outcomes 
 
Figure 2: Meta-regression of relationship between mean change in HOMA-IR and the mean 
change in BMI-SDS (n=105 subsets). 
 
Figure 3: Meta-regression of relationship between mean change in fasting glucose and the mean 
change in BMI-SDS (n=92 subsets) 
 
Figure 4: Meta-regression of relationship between mean change in ALT and the mean change in 
BMI-SDS (n=28 subsets) 
 
Figure 5: Meta-regression of relationship between mean change in CRP and the mean change in 




Figure A(i) Half normal plot for the predicted random effects from the meta-regression of the 
mean change in HOMA-IR and the mean change in BMI SDS (n=105, see main text). 
 
Figure A(ii) Meta-regression of relationship between mean change in HOMA-IR and the mean 




Figure A(iii) Meta-regression of relationship between mean change in HOMA-IR and the mean 
change in BMI-SDS using only the 22 data subsets where the mean and SD of the changes are 
given in the paper. 
 
Figure B(i) Half normal plot for the predicted random effects from the meta-regression of the 
mean change in fasting glucose and the mean change in BMI SDS (n=92, see main text). 
 
Figure B(ii) Meta-regression of relationship between mean change in fasting glucose and the 
mean change in BMI-SDS after excluding two outliers (n=90, see main text). 
 
Figure C(i) Half normal plot for the predicted random effects from the meta-regression of the 
mean change in ALT and the mean change in BMI SDS (n=28, see main text). 
 
Figure D(i) Half normal plot for the predicted random effects from the meta-regression of the 
mean change in CRP and the mean change in BMI SDS (n=36, see main text). 
 
Supplementary material 
Figure 6: Venn diagram to show the different number of studies included in the three different 
papers. 

































A total of 16383 references retrieved. 
8318 duplicates removed, 8065 titles 
and abstracts assessed 
7815 articles excluded based on the title 
and abstract. Reasons for exclusion were 
as a result of the papers not being related 
to obesity, did not look at children, not a 
lifestyle intervention, no markers of 
metabolic health reported and no change 
in BMI/SD reported. 
250 full text articles retrieved  
Total number of articles included = 
98 (90 studies) 
17 papers from hand searching of 
full text articles (3 excluded) 
N=14 
Total excluded: 166 articles  
Not in age range = 16 
Does not set BMI-SDS scores = 17 
BMI (OW +/or OB) or no diagnosis of obesity 
=66 
Cross-sectional study = 1 
No results presented =1 
Not a behaviour/lifestyle intervention =12 
Data only measured at one time point = 9 
Measure of psychological well-being only = 3 
BMI-SDS only measured post-intervention = 1 
Outcome: Difference in BMI-SDS based on age 
of participants = 1 
Only one relevant outcome =1 
Systematic review = 1 
No outcome of interest =16 
Abstract or on-going study = 17 
HOMA as predictor of BMI response (HOMA 
measured as predictor of weight loss, not as 
outcome) = 2 




Appendix 2  
Fig A(i) Half normal plot for the predicted random effects from the meta-regression of the 
mean change in HOMA-IR and the mean change in BMI SDS (n=105, see main text). 
INSERT HERE 
 
Figure A(ii) Meta-regression of relationship between mean change in HOMA-IR and the 
mean change in BMI-SDS. 
Figure A(ii) shows the meta-regression of Figure 2 in the main paper but highlights (in red) the 4 
study subsets where geometric means were used interchangeable with medians. The results 
seemed consistent with the remainder and their exclusion did not change our overall findings 
(not shown). 
 INSERT HERE 
 
 
Figure A(iii) Meta-regression of relationship between mean change in HOMA-IR and the 
mean change in BMI-SDS using only the 22 data subsets where the mean and SD of the 
changes are given in the paper. 
The fitted regression line was Mean fall in HDL = 1.498 x Mean change in BMISDS + 0.022. 
From these limited data, we could not determine a mean change in BMI-SDS that would ensure a 
mean reduction of HOMA-IR; there was a weak relationship between these values that failed to 




Fig B(i) Half normal plot for the predicted random effects from the meta-regression of the 
mean change in fasting glucose and the mean change in BMI SDS (n=92, see main text). 





Figure B(ii) Meta-regression of relationship between mean change in fasting glucose and the 
mean change in BMI-SDS after excluding two outliers (n=90, see main text). 
The meta-regression line fitted was: Mean fall in Glucose = 0.075 x Mean change in BMISDS 
-0.006. The small positive slope was not statistically significant (P=0.068). From the prediction 
intervals, it was not possible to determine a mean reduction in BMI Z-score that would ensure a 





Fig C(i) Half normal plot for the predicted random effects from the meta-regression of the 




Fig D(i) Half normal plot for the predicted random effects from the meta-regression of the 
mean change in CRP and the mean change in BMI SDS (n=36, see main text). 
 
INSERT HERE  
 
 
Appendix 1:  
Eligibility criteria for inclusion to the systematic review  
Participants 
Studies with participants aged 4–19 years with a diagnosis of obesity using defined BMI thresholds 
were considered for inclusion. BMI-SDS was calculated as a function of the degree of obesity of 
the subjects when compared with BMI standards. BMI standards included, but were not limited to, 
the 98th centile on the UK 1990 growth reference chart28, 95th percentile on the US Centre for 
Disease Control and Prevention growth chart29, the International Obesity Taskforce (IOTF) BMI 
for age cut-points30 and the World Health Organisation growth references 31,32, in addition to 
country-specific obesity thresholds using BMI reference data from their paediatric populations. 
Studies that included overweight, as opposed to obese, individuals, pregnant females, or those with 
a critical illness, endocrine disorders or syndromic obesity were excluded from this review.  
 
Interventions 
Studies of lifestyle treatment interventions that included dietary, physical activity and/or 
behavioural components with the objective of reducing obesity were included. Interventions of less 
than 2 weeks duration and those that involved surgical and/or pharmacological components (e.g. 
bariatric surgery, drug therapy) were excluded. Studies focused on obesity prevention were also 
excluded. No restrictions were imposed regarding the setting or delivery of the interventions.  
 
Outcome measures 
To meet the inclusion criteria interventions had to report baseline (pre-) and post-intervention BMI-
SDS/z-score or change measurements of BMI-SDS/z-score plus one or more of the following 
markers of metabolic health: 
• Adiposity measures other than BMI (including waist circumference and percentage body fat)  
• Glucose 
• Insulin sensitivity/resistance (homeostatic model assessment (HOMA)) 
 
 
• Lipid profile (triglycerides, total cholesterol, low-density lipoprotein (LDL)/high-density 
lipoprotein (HDL) cholesterol)  
• Inflammation (C-reactive protein) 
• Blood pressure (systolic, diastolic) 
• Liver function 
 
This paper focuses on the inflammation, diabetes and liver function measures only. Further papers 
in this series will report on other outcome measures. 
 
Study design  
Completed, published, randomised controlled trials (RCTs) and non-randomised studies (cohort 
studies) of lifestyle treatment interventions for obese children and adolescents, with or without 
follow-up.  
 
Information sources and search methods 
Studies were identified by searching five electronic databases from inception to May 2017, 
alongside scanning reference lists of included articles and through consultation with experts in the 
field.  
 
Study Selection and data extraction 
Titles and abstracts were assessed for eligibility and data were extracted by two independent 
reviewers from the review team (LB, AC, RP, RB, RM).  
 
 
 
 
 
 
 
